cangrelor 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
platelet aggregation inhibitors 5006 163706-06-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • canegrelor
  • cangrelor
  • cangrelor tetrasodium
  • kengreal
  • AR-C69931XX
  • AR-C69931MX
  • kengrexal
  • ARL69931
Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.
  • Molecular weight: 776.35
  • Formula: C17H25Cl2F3N5O12P3S2
  • CLOGP: 2.23
  • LIPINSKI: 3
  • HAC: 17
  • HDO: 7
  • TPSA: 255.91
  • ALOGS: -2.25
  • ROTB: 16

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg P

ADMET properties:

Approvals:

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

cangrelor